GenSpera acquires cancer imaging technology patent
Oncology company GenSpera has acquired a patent application for technology relating to medical imaging from the Sydney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore and the University of Copenhagen in Denmark.
According to the San Antonio-based company, the technology includes derivatives of thapsigargin, the active ingredient in GenSpera’s therapeutics program, as well as its patented tumor-targeted peptides to create cancer-specific imaging compounds. In addition, the technology allows for the detection and monitoring of tumors when used in conjunction with modalities such as PET or SPECT.
According to the San Antonio-based company, the technology includes derivatives of thapsigargin, the active ingredient in GenSpera’s therapeutics program, as well as its patented tumor-targeted peptides to create cancer-specific imaging compounds. In addition, the technology allows for the detection and monitoring of tumors when used in conjunction with modalities such as PET or SPECT.